Premium
The role of Hippo/yes‐associated protein signalling in vascular remodelling associated with cardiovascular disease
Author(s) -
He Jinlong,
Bao Qiankun,
Yan Meng,
Liang Jing,
Zhu Yi,
Wang Chunjiong,
Ai Ding
Publication year - 2018
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.13806
Subject(s) - vascular remodelling in the embryo , hippo signaling pathway , angiogenesis , biology , restenosis , microbiology and biotechnology , vascular smooth muscle , extracellular matrix , effector , hedgehog signaling pathway , signal transduction , cancer research , medicine , endocrinology , smooth muscle , stent
Vascular remodelling is a vital process of a wide range of cardiovascular diseases and represents the altered structure and arrangement of blood vessels. The Hippo pathway controls organ size by regulating cell survival, proliferation and apoptosis. Yes-associated protein (YAP), a transcription coactivator, is a downstream effector of the Hippo pathway. There is growing evidence for the importance of the Hippo/YAP pathway in vascular-remodelling and related cardiovascular diseases. The Hippo/YAP pathway alters extracellular matrix production or degradation and the growth, death and migration of vascular smooth muscle cells and endothelial cells, which contributes to vascular remodelling in cardiovascular diseases such as pulmonary hypertension, atherosclerosis, restenosis, aortic aneurysms and angiogenesis. In this review, we summarize and discuss recent findings about the roles and mechanisms of Hippo/YAP signalling in vascular remodelling and related conditions.